Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis1Studies supported by the National Multiple Sclerosis Society (grants RG2019, RG2827); the NINDS (NS26321); and Biogen Inc.1

Authors:
  • DCDiane L. Cookfair
    Diane L. Cookfair
  • NSNancy A. Simonian
    Nancy A. Simonian
  • RRRichard M. Ransohoff
    Richard M. Ransohoff
  • JRJohn R. Richert
    John R. Richert
  • LJLawrence D. Jacobs
    Lawrence D. Jacobs
  • RHRobert M. Herndon
    Robert M. Herndon
  • ASAndres M. Salazar
    Andres M. Salazar
  • JFJill S. Fischer
    Jill S. Fischer
  • CGCarl V. Granger
    Carl V. Granger
  • DGDonald E. Goodkin
    Donald E. Goodkin
  • JSJack H. Simon
    Jack H. Simon

Abstract
No abstract available

This publication has 23 references indexed in Scilit: